The Medical Technology Enterprise Consortium has awarded a BioBridge Global-led group of organizations a three-year, $7.8 million contract to develop a clinical-grade process for stem cell manufacturing techniques.
BBG said Monday the team will work to create large-scale stem cell manufacturing economical platforms in an effort to give researchers human bone marrow-derived mesenchymal stem cells for study, therapeutic and clinical use.
Xeno-free biomanufacturing processes for stem cells are designed to maintain the critical quality attributes of stem cells for use in regenerative medicines where stem cells are applied in an effort to regenerate damaged tissues and organ systems.
BBG says stem cells have the potential to help with three-dimensional bioprinting and treatments for non-healing wounds, bone fractures, soft tissue injuries and ischemic heart disease min injured soldiers, military dependents, retirees and civilians.
The team comprised of BBG, the U.S. Army Institute of Surgical Research Coagulation and Blood Research, StemBioSys and RoosterBio will also seek to expand present novel hMSC product platforms, create a novel, xeno-free nutrient source for hMSCs, evaluate media components and build assays for hMSCs safety tests.
A number of universities, commercial centers and other potential end uses, such as Mayo Clinic will provide additional support for the project.